Search
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalImlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. The FDA approved imlunestrant on September 25, 2025 as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-muta...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBenzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigationalBenzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesHydrastine
go.drugbank.com/drugs/DB19354ExperimentalCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 SubstratesEquilenin
go.drugbank.com/drugs/DB03515ExperimentalEquilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigationalTiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transport...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersRibostamycin
go.drugbank.com/drugs/DB03615ApprovedWithdrawnRibostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.
Phenacetin
go.drugbank.com/drugs/DB03783ApprovedWithdrawnPhenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates6-Deoxyerythronolide B
go.drugbank.com/drugs/DB04070ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsHypoxanthine
go.drugbank.com/drugs/DB04076InvestigationalHypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTaurocholic acid
go.drugbank.com/drugs/DB04348ApprovedThe product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagog...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates